# Project Proposals: Mithun Chowdhury

## Project Title: Bio-Inspired Adaptive Nanoplasmonic Soft Matter for Autonomous Wound Healing 

### 1. Vision and Scope

**What is the project's overarching goal?**

The overarching goal of this project is to develop a new class of bio-inspired, adaptive, and autonomous wound healing materials that leverage the combined power of plasmonics, soft matter, and synthetic biology.  This innovative material will be capable of:

1. **Sensing the wound environment:** Detecting the presence of bacteria and inflammatory markers, the pH level, and the temperature of the wound.
2. **Responding adaptively:**  Releasing specific antimicrobial agents or therapeutic molecules in a controlled manner based on real-time sensing data.
3. **Promoting tissue regeneration:**  Actively stimulating cell growth and tissue repair through localized heating generated by plasmonic nanoparticles. 
4. **Self-healing:**  Repairing any damage to the material itself, ensuring long-term functionality and effectiveness. 

**What change or impact does the project aim to achieve on a global, regional, or local scale?**

This project aims to transform wound healing practices globally, leading to:

* **Reduced healing times:**  Significantly accelerating the healing process of chronic wounds and reducing the burden on healthcare systems.
* **Improved patient outcomes:**  Minimizing scar tissue formation and reducing the chance of infection, leading to better aesthetic and functional outcomes for patients.
* **Development of personalized therapy:** Tailoring treatment based on the specific needs of each wound and patient.
* **Reduced antibiotic resistance:** Targeting antimicrobial treatments to the site of infection, aiding in the global fight against antibiotic resistance.
* **Broader impact on soft matter design:** Advancing the field of Intelligent Soft Matter by demonstrating the feasibility of combining sensing, actuation, and self-repair functionalities into a single material. 

**How does it connect to current societal, environmental, or scientific challenges?**

* **Ageing Population:** An increasing global elderly population poses challenges for healthcare, particularly related to wound healing, making innovative solutions extremely relevant.
* **Antibiotic Resistance:**  The project aims to combat antibiotic resistance by implementing targeted antimicrobial delivery.
* **Materials Science Advancement:** This project pushes the frontiers of soft matter research, offering potential solutions across diverse domains.

**What distinguishes this initiative from other similar projects?**

This project leverages a unique combination of technologies not yet implemented in a single system:

1. **Plasmonics for Controlled Heating and Therapy:** Utilizing plasmonically active gold nanostars (synthesized by **Miguel Correa-Duarte**, expert in plasmonic nanoparticle synthesis), to generate localized heat upon laser irradiation. The heat can stimulate cell growth and be used for controlled release of therapeutics. 
2. **Bio-inspired Polymer Matrix for Sensing and Actuation:** Designing a stimuli-responsive polymer scaffold (developed by **Se-Hyeong Jung**, expert in stimuli-responsive polymers and hydrogels)  capable of sensing specific molecules and releasing encapsulated therapeutics. The polymer will be designed to respond  to changes in pH (indication of infection), temperature, and the presence of specific biomarkers related to inflammation.
3. **Synthetic Biology for Targeted Antimicrobial Release:** Integrating engineered bacteria (designed by **Martin Hanczyc**, expert in artificial cells), that sense bacterial pathogens and release targeted antimicrobial peptides. This will enable precise treatment of infections while minimizing collateral damage to beneficial bacteria. 

**Why is the project needed now?**

* **Urgent Need for Innovation:** Chronic wounds are a major healthcare burden, with current treatments often ineffective or slow.
* **Technological Advancements:** Recent advancements in plasmonics, soft matter, and synthetic biology provide the tools to develop this solution only now. 
* **Growing Importance of Intelligent Soft Matter:** The timing aligns with increasing recognition of the transformative potential of merging materials with adaptive functionalities.

### 2. Problem Statement

**What is the root cause of the issue the project addresses?**

Chronic wounds pose a significant challenge to healthcare, with root causes stemming from:

* **Systemic factors:**  Increased prevalence of diabetes and other conditions that impair wound healing. 
* **Structural factors:** Limited access to specialized wound care, inadequate treatment protocols, and a lack of personalized approaches.
* **Behavioral factors:** Patient non-compliance with wound care instructions, particularly in self-management.

These factors contribute to a complex problem where wounds fail to heal in a timely manner, leading to pain, infection, decreased quality of life, and a high healthcare cost.

**What evidence supports the importance of addressing this issue?**

* **Global Prevalence:** The World Health Organization estimates 6.5 million people suffer from chronic wounds annually.
* **Economic Burden:** The global wound care market is projected to reach \$27.2 billion by 2027, demonstrating the significant economic burden of treating chronic wounds. 
* **Patient Suffering:** Chronic wounds significantly diminish quality of life and are associated with pain, depression, and social isolation.
* **Risk of Inaction:** Untreated chronic wounds can lead to serious complications including amputation, sepsis, and even death. 

### 3. Proposed Solution and Key Innovation

**What is the central idea or mechanism behind the project's solution?**

This project leverages a **multi-layered bio-inspired soft matter material** that mimics the natural healing process while integrating advanced technologies:

1. **Sensing Layer:** The **stimuli-responsive polymer matrix acts as the sensing layer**.  It contains specific molecular sensors (e.g., aptamers) designed to detect biomarkers for infection (pH change, inflammatory markers), temperature, and specific pathogens. Upon detection, these sensors trigger a conformational change in the polymer, leading to the release of specific molecules.
2. **Actuation & Healing Layer:** The polymer matrix also incorporates **plasmonically active gold nanostars** and encapsulated therapeutics.  Near-infrared (NIR) light, harmless to surrounding tissue, is used to irradiate the material. The gold nanostars absorb NIR light, generating localized heat focused in the wound area. This localized heat: 
    * **Promotes tissue regeneration:** Stimulating cell growth and blood vessel formation.
    * **Triggers controlled release:**  By activating temperature-sensitive mechanisms within the polymer, carefully releasing the required concentration of encapsulated growth factors and other therapeutics at the site of injury.
3. **Antimicrobial Layer:**  A separate layer of the material contains encapsulated **engineered bacteria** that specifically target and kill pathogenic bacteria upon sensing their presence. The bacteria release pre-programmed antimicrobial peptides that are highly specific to common wound pathogens.

**How does the solution improve upon or differ from existing approaches?**

* **Integrated Functionality:** Combines sensing, therapeutic delivery, and antimicrobial action into a single material, offering a multifaceted and dynamic approach to wound healing. 
* **Autonomous and Adaptive:**  The material responds to the wound's changing environment in real-time, tailoring the treatment based on immediate needs, minimizing unnecessary interventions. 
* **Bio-inspired Design:** Mimics natural healing processes by promoting tissue regeneration, while also providing self-healing functionality in case of material damage.



### 4. Network and Collaboration

**Who are the primary contributors to the project?**

* **Project Lead:**  Mithun Chowdhury -  Expertise in characterizing the dynamics and properties of thin polymer films, providing a foundation for this material design.
* **Plasmonics Expert:** Miguel Correa-Duarte -  Responsible for the synthesis, size control, and characterization of plasmonically active gold nanostars.
* **Soft Matter Polymer Scientist:**  Se-Hyeong Jung -  Designs and synthesizes the stimuli-responsive polymer matrix, incorporates sensor molecules, and optimizes for controlled release.
* **Synthetic Biology Expert:**  Martin Hanczyc -  Engineers bacteria to specifically target and kill wound pathogens through programmed antimicrobial peptide release.
* **Computational Biologist:** (To be recruited) - Develops a computational model for predicting material behavior, optimizes design through simulations, and potentially integrates AI for real-time feedback control. 

**How will the project create and sustain collaboration?**

* **Regular Meetings:** Frequent virtual and in-person meetings will ensure consistent communication and coordinated efforts. 
* **Joint Authorship & Publications:**  Shared authorship on publications will incentivize collaboration and ensure recognition for all contributors.
* **Joint Funding Proposals:**  Collaborative proposals for funding will create the financial support for sustained development and exploration.  
* **Open-Science Principles:** Sharing experimental protocols, data, and code openly will encourage engagement and promote reproducibility.

### 5. Knowledge Integration and Sharing

**What types of data, methods, or resources will the project use?**

* **Materials Characterization:**  Utilizing a range of experimental techniques including:
    * **Atomic Force Microscopy (AFM):**  For analyzing surface topography of polymer films and nanoparticle distribution.
    * **Dynamic Light Scattering (DLS):** Measuring the size and stability of gold nanostars and microgels.
    * **Spectroscopy:**  UV-Vis and fluorescence spectroscopy to determine optical properties of plasmonic systems.
    * **Rheology:** Studying the mechanical properties and viscoelastic behavior of the polymer matrices.
* **Computational Modeling:** Employing simulations to: 
    * **Predict Material Response:**  How the material reacts to stimuli and interacts with the wound environment.
    * **Optimize Design:**  Tailoring material properties for specific applications. 
    * **Explore Potential of AI:** Investigating potential for integrating machine learning for dynamic feedback control. 
* **Biological Characterization:**  Performing experiments to:
    * **Validate Antimicrobial Activity:**  Testing the efficacy of engineered bacteria against target pathogens. 
    * **Assess Biocompatibility:** Ensured the material is safe for use in living systems.
    * **Monitor Wound Healing:** Tracking wound closure and tissue regeneration in in-vitro and in-vivo models.  

**How will the project share its findings?**

* **Peer-Reviewed Publications:** Publishing results in high-impact, open-access journals to disseminate knowledge to the scientific community.
* **Open Data Platforms:**  Depositing experimental data in open repositories for transparency and encourage further analysis by others.
* **Preprints and Conference Presentations:** Disseminating findings early through preprints and actively participating in conferences to foster discussion and collaboration.
* **Patents and Technology Transfer:**  Actively pursuing patent protection for innovative technologies developed in the project, with the focus on technology transfer to bring the solution to practical use in the healthcare sector.

### 6. Implementation Plan

**Phases of Development**

1. **Exploration Phase (Year 1)**
    * **Define Specific Targets:**  Identify the specific types of chronic wounds to target initially (e.g., diabetic foot ulcers).
    * **Develop Prototype Materials:**  Synthesize and characterize individual components of the material and test their functionalities independently.
   * **Validate Computational Models:** Develop a preliminary computational model of the material system for predicting behavior under various conditions.

2. **Design & Build Phase (Years 2-3)**
    * **Integrate Components:** Combine the individually synthesized components to create the multi-layered intelligent soft matter material.
    * **Optimize Material Properties:** Fine-tune the materials based on experimental and simulation data to achieve optimal sensing, actuation, and healing properties.
    * **In-vitro Validation:** Test the material's performance in controlled laboratory settings, simulating the wound environment. Develop biocompatibility testing protocols and validate the long-term stability and functionality of the engineered material. 

3. **Deployment Phase (Year 4)**
    * **Animal Model Testing:**  Begin pre-clinical trials with animal models to assess safety, efficacy, and biocompatibility in a living organism.
    * **Clinical Trial Preparation:**  Start preparing for regulatory approval and human clinical trials based on the positive results from the pre-clinical studies.
    * **Develop Manufacturing Protocols**: Explore scalable and cost-effective methods for manufacturing the material system, including the integration and optimization of different fabrication techniques.

 4. **Scaling & Legacy Phase (Year 5 onwards)**
    * **Initiate Human Clinical Trials:**  
        * Conduct pilot clinical trials for testing the intelligent soft matter material on human patients with chronic wounds.
        * Based on the positive results from clinical trials, optimize manufacturing process and commercialization strategies.
    * **Broaden Applications:** Explore the potential of the developed technology for other biomedical applications and intelligent soft material designs. 
    * **Disseminate Knowledge:**  Document findings, create training programs for clinicians, and promote awareness of this new technology.

**Methodologies and Approaches**

* **Iterative Design:**  The project will follow an iterative design process, continuously refining the material based on experimental and computational data, utilizing feedback from collaborating partners and potentially integrating machine learning for optimized adaptation.
* **Interdisciplinary Approach:** This project inherently necessitates a highly interdisciplinary approach, with strong communication and knowledge exchange between the diverse expertise of collaborators.
* **Open Science Practices:** The project will embrace open science principles to maximize transparency, reproducibility, and collaboration, as mentioned in the knowledge integration and sharing section.

### 7. Data and Decision-Making Framework 

**What role does data play in the project's strategy?**

* **Guiding Material Design:** Initial stages will heavily rely on data from experimental characterization to inform the material design and fabrication, along with computational modelling for simulating material properties.
* **Validating Functionality:** Data from both in-vitro and in-vivo experiments will serve as the basis for testing the material's effectiveness and safety in real-world scenarios.
* **Adaptive Control (Potential):**  In later stages of development, real-time data from sensor feedback could potentially be used to guide and adapt the material's behavior in a personalized manner.

**What mechanisms will ensure transparency and accountability?**

* **Open Data Sharing:** All experimental data, including those related to fabrication, characterization, performance, and material properties, will be deposited in publicly accessible open data repositories after publication.
* **Pre-registration of Studies:**  All in-vitro and in-vivo experiments will be pre-registered on public platforms, outlining the specific hypotheses, methodologies, and analysis plans before the study begins. This prevents outcome switching based on the results and ensures transparency in the research process.
* **Ethical Review Board:**  The project will be overseen by an ethical review board, which includes experts from various fields, to ensure compliance with ethical guidelines and potential societal impacts. The board will guide research practices, providing independent evaluation of the safety and the implications of the developed technologies. 

### 8. Impact and Real-World Relevance

**What is the intended outcome for users, communities, or systems?**

The intended outcome includes: 

* **For Patients:**
    * Faster wound healing, minimizing pain, scarring, and risk of infection. 
    * Improved quality of life from reduced treatment time and increased mobility.
* **For Healthcare Systems:**
    * Reduced hospital stays and costs associated with treating chronic wounds.
    * Increased effectiveness of wound care, leading to more efficient use of resources.
* **For the Scientific Community:**
    * Advancement of the field of intelligent soft matter through demonstration of highly integrated functionalities.
    * Promoting interdisciplinary research and open scientific practices. 

**Metrics for Success:**

* **Wound Closure Rate:** Measuring the time it takes for wounds to heal in comparison to existing treatments.
* **Reduced Infection Rates:**  Comparing infection incidence in patients treated with this material to those receiving standard care.
* **Scar Formation:**  Evaluating the aesthetic and functional outcomes of healed wounds and minimizing scar tissue formation. 
* **Patient Satisfaction Surveys:** Assessing pain levels, comfort, and overall experience with the new treatment. 

**How does the project address ethical or equity considerations?**

* **Accessibility and Affordability:** The project will focus on developing a cost-effective solution that is accessible to a diverse patient population, regardless of socio-economic background. This will be a core objective during the design and manufacturing stages.
* **Safety Testing:** Rigorous safety and biocompatibility testing will be conducted throughout the development process, ensuring the material poses minimal risk to patients and healthcare workers.
* **Transparency and Open Science:** The project will prioritize open communication and data sharing to foster trust, accountability, and broader accessibility of the technology.
* **Representation in Clinical Trials:**  Care will be taken to ensure diverse representation in clinical trials, considering factors like age, gender, ethnicity, and underlying health conditions, to minimize bias and determine any potential differences in treatment response. 

### 9. Risks and Adaptability 

**What are the potential risks and how will they be managed?** 

* **Technical Risks:**
    * **Material Integration Challenges:** Combining different components could lead to unexpected interactions or difficulties in achieving desired properties. 
    * **Scaling of Manufacturing:**  Transitioning from lab-scale production to mass production could present difficulties. 
    * **Mitigation:**  Close collaboration between researchers, iterative design process, comprehensive prototyping will be key. 
* **Financial Risks:**
    * **Funding Gaps:** Securing sustained funding throughout the development timeline might be challenging.
    * **Mitigation:** Actively pursuing diverse funding sources (government grants, private investment), building strategic partnerships will be crucial. 
* **Social and Ethical Risks:**
    * **Unforeseen Biocompatibility Issues:**  The material, although extensively tested, might exhibit unexpected side effects or long-term complications. 
    * **Data Privacy Concerns:**  Integration of AI and real-time monitoring requires ensuring the privacy and security of patient data.
    * **Mitigation:** Constant ethical review, ongoing monitoring for potential side-effects, robust data encryption protocols are essential.

**Adaptability**

* **Flexible Development Timeline:** The timeline will be adaptable, allowing for adjustments and delays in response to unforeseen challenges or new discoveries.
* **Contingency Plans:** Alternative approaches and backup strategies will be developed in case a specific component or methodology proves ineffective. 
* **Continuous monitoring and evaluation:**  Regularly assessing progress and adjusting course based on the results from experiments, simulations, and feedback from the scientific community and potential users. 

### 10.  Long-Term Vision and Scaling

**What is the legacy of the project?**

* **Scientific Legacy:**
    *  Demonstrate the potential for merging soft matter, plasmonics, and synthetic biology to create a new class of "intelligence embedded in materials."
   *  Generate a wealth of knowledge about material behavior, biological control, and the thermodynamics of non-equilibrium systems relevant to the design of future intelligent materials.
    *  Develop new computational models and design principles that are transferable to other soft matter systems.
* **Social Legacy:**
    *  Establish a framework for collaboration and open science in a highly interdisciplinary field.
    *  Contribute to more effective, personalized, and affordable healthcare for wound management.  

**How will the project scale?**

* **Commercialization and Partnerships:**  The project will actively seek partnerships with medical device companies, healthcare providers, and government agencies to facilitate the: 
    *  **Manufacturing:** Scaling up production for wider distribution of the new wound healing materials.
    * **Clinical Integration:** Implementing these materials into clinical practices and adapting existing treatment protocols.
* **Education and Outreach:**  Training materials and workshops for clinicians will be developed to educate healthcare professionals on appropriate application of this new technology and the best practices.


 **How will the project sustain itself or its outcomes after initial implementation?**

* **Long-Term Funding:**  The project will explore sustainable funding models, such as creating a spin-off company or obtaining licensing agreements for the developed technologies. 
* **Ongoing Research:**  Continuous funding for research will be sought to further refine the technology and expand the scope of applications.
* **Open Source Platforms:**  Key computational models and design principles will be made available as open-source resources for the scientific community. 

### 11. Community Engagement and Open Innovation 

**How will stakeholders participate in the project?**

* **Clinician Feedback:**  Regular advisory meetings with clinicians specializing in wound care to gather input on usability, potential challenges, and adaptation to diverse clinical needs. 
* **Patient Input:**  Engagement with patient advocacy groups to understand patient perspectives, concerns, and incorporate those insights into the design phase.
* **Open Collaboration Channels:** Creating online forums, scientific wikis, and collaborative workshops to enable continuous feedback and input from researchers in related fields.

**What role does open innovation play in its design?**

* **Open Source Tools and Data:** The project will actively release computational tools, experimental protocols, and processed data sets in open and accessible platforms for other researchers and engineers to further develop and exploit the technology.
* **Collaborative Development:** The project encourages participation from the external community in various aspects, including the validation of experimental protocols, model development and feedback on material design and functionalities.
* **Open Licensing Agreements:** When patents are filed, open and fair licensing agreements will be promoted to encourage wider adoption and commercialization of the technology by other stakeholders within the biomaterials, medical devices, and healthcare technology industries.

This approach to community engagement and open innovation will foster knowledge transfer, accelerate the rate of technological advancements and ensure that the benefits of the project extend far beyond its creators.
